Outcomes for four of the five endpoints (survival 7 days after end of therapy, discontinuation of therapy, resolution of fever, successful treatment of any baseline fungal infection) favored liposomal amphotericin B but did not reach statistical significance.
← all excerpts
Update on the optimal use of voriconazole for invasive fungal infections.
1
—
—